Myoview (Tetrofosmin)

Tetrofosmin, the active ingredient in Myoview, is a radiopharmaceutical presented as a 10 mCi (370 MBq) sterile solution for injection for intravenous use. It enables visualization of myocardial blood flow, supporting the diagnosis and management of coronary artery disease and assessment of myocardial viability in cardiac SPECT studies.

GNH USA supplies Myoview as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and cardiac imaging centres worldwide, with established distribution networks across Europe, Asia and the Americas, and adhering to stringent quality standards.

Myoview (technetium‑99m tetrofosmin) is used in cardiac imaging to evaluate myocardial perfusion and related conditions. - Myocardial perfusion imaging: enables detection of regional blood flow defects during stress and rest studies. - Coronary artery disease detection: helps identify ischemic territories associated with obstructive lesions. - Myocardial viability assessment: distinguishes viable from scarred myocardium for revascularization planning. - Stress/rest cardiac SPECT imaging: provides comparative images to assess inducible ischemia.

Adverse reactions to Myoview are generally infrequent but may occur following intravenous administration of the radiopharmaceutical. Common Side Effects: - Injection site pain: mild discomfort at the venipuncture site. - Nausea: transient feeling of queasiness. - Headache: mild to moderate headache. Serious or Rare Side Effects: - Allergic reaction: urticaria, bronchospasm or anaphylaxis. - Hypotension: significant drop in blood pressure. - Arrhythmia: new onset cardiac rhythm disturbances.

Prior to using Myoview, clinicians should consider several precautionary measures to ensure patient safety and optimal image quality. - Pregnancy: use only if the diagnostic benefit outweighs potential fetal radiation risk. - Breastfeeding: discontinue nursing or pump and discard milk for 24 hours after administration. - Renal impairment: assess renal function as clearance may be reduced. - Thyroid disorders: consider iodine blockade to reduce thyroid uptake of free technetium. - Concurrent cardiac medications: beta‑blockers or nitrates may affect perfusion results; adjust protocol accordingly. Store at ambient temperature: keep vials in original container, protect from light and moisture, and do not freeze.

Myoview may interact with certain drugs or substances that influence myocardial blood flow, radiotracer distribution, or radiation safety. Major Interactions (Avoid): - Thyroid hormone therapy: may increase thyroid uptake of free technetium, raising radiation exposure. - Iodine‑containing contrast agents: can compete with technetium uptake, reducing image quality. - High‑dose vasodilators: may alter myocardial perfusion patterns and affect interpretation. Moderate Interactions (Monitor Closely): - Beta‑blockers: can blunt stress‑induced hyperemia, potentially leading to false‑negative results. - Calcium channel blockers: may modify coronary flow reserve, influencing tracer distribution. - Caffeine or methylxanthines: should be avoided before stress testing as they antagonize vasodilator agents.